Trevi Therapeutics, Inc

[Not Yet Scheduled]
Trevi Therapeutics, Inc. (Nasdaq: TRVI) is a clinical-stage biopharmaceutical company developing an investigational oral therapy Haduvio™ (nalbuphine ER). Trevi is conducting a Phase 2b/3 clinical trial of Haduvio for the treatment of chronic pruritus associated with prurigo nodularis (PN) and a Phase 2 trial for chronic cough in patients with idiopathic pulmonary fibrosis (IPF). These conditions both are areas of high unmet need and share a common pathophysiology that is mediated through the kappa and mu opioid receptors in the central and peripheral nervous systems. Trevi Therapeutics recently reported a statistically significant result on the interim analysis from the Ph2 CANAL trial of nalbuphine ER in the treatment of chronic cough in IPF for cough reduction (p<0.0001). Upcoming clinical milestones include topline data from the PRISM study of chronic pruritus in PN in Q2 2022, and topline data for all subjects enrolled in CANAL study of chronic cough in IPF in Q3 2022.
Ticker:
TRVI
Exchange:
NASDAQ
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Connecticut
Company HQ Country:
United States
Year Founded:
2011
Main Therapeutic Focus:
Lead Product in Development:
Haduvio (nalbuphine ER)
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
1
Speaker
photo
President & CEO
Trevi Therapeutics